Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The biomarker changes (lower blood pressure, better lipid profile) are favourable and create a reasonable prior expectation, but the dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes) is not expected to report until late 2027 or early 2028
In the SURMOUNT-1 trial, participants without diabetes lost an average of 15-22% of their body weight over 72 weeks, depending on the dose (5-15mg)
Retatrutide is an investigational triple agonist designed to activate three metabolic receptors at once: GLP-1, GIP, and glucagon
Briskin, M
It's a highly specific and modified version of a naturally occurring hormone, and that modification is everything
US$ 27.86
US$ 21.19
US$ 24.00
US$ 23.12
US$ 27.47
US$ 26.63
